Introduction
Sudden unexpected death in epilepsy (SUDEP) refers to sudden death with or without evidence of seizure among seemingly healthy individuals with epilepsy; by definition, SUDEP is not attributed to trauma, drowning, status epilepticus, or other known causes [1, 2] . Recent clinical studies have focused on SUDEP, and public and political recognition of this condition has increased [2] . The overall incidence rate of sudden death is more than 20 times higher in patients with epilepsy than in the general population [3] and varies depending on the study population [1] . In general epilepsy populations, incidence rate of SUDEP is low, and in individuals with chronic refractory epilepsy the rate is higher and highest in epilepsy surgery candidates [1] . A previous review [2] concluded an incidence of SUDEP per 1000 patient-years was 0.09-2.65 in community samples, 1.2-5.9 in tertiary care epilepsy centers, and 6.0-9.3 among patients evaluated for or treated with surgery or vagus-nerve stimulation for epilepsy.
The few existing epidemiological surveys suggest that the frequency of tonic-clonic seizures could be the most prominent factor affecting SUDEP [4] [5] [6] [7] . Additional risk factors include the lack of antiepileptic drug (AED) treatment, frequent changes in therapy with AEDs, AED polytherapy, early adulthood, epilepsy of long duration, and mental retardation [6, [8] [9] [10] 4] . To the best of our knowledge, studies on the risk of SUDEP in China and other low-middle income countries are lacking. In the present study, we determined the risk factors of probable SUDEP in a rural community sample with convulsive epilepsy in West China on the basis of an established network of epilepsy management [11] . The network is under unified leadership of the public health administration departments, who liaise with medical institutions and disease control and prevention organizations to foster local communities to participate. The results of this study may provide insights into the probable SUDEP of patients in our region and possible prevention against probable SUDEP.
Methods

Study sites and study population
This study explored the characteristics of probable SUDEP in a population with convulsive epilepsy in rural communities of West China. As part of an epilepsy management program, 16 target counties ( Fig. 1 ) covering a population of 10.5 million individuals in rural West China were selected to undergo a convulsive epilepsy screening followed by pragmatic phenobarbital (PB) monotherapy at the primary care level from May 2005 to December 2013. The Sichuan University Ethical Standards Committee on Human Experimentation provided ethical approval of the project. All participants or guardians for children aged <18 years provided their written informed consent.
Patient selection
Project background and operation procedures were elaborately illustrated in previous reports [12] [13] [14] [15] . In accordance with the rural management program, patients with convulsive epilepsy in each target county were identified at the first year and received PB intervention during follow-up. In these programs, primary healthcare physicians provided the initial diagnosis of active convulsive epilepsy among participants, which was later confirmed by supervising neurologists (2-4 supervising neurologists from tertiary hospital were assigned to each target area) in accordance with strict criteria. In this study, patients with convulsive epilepsy were defined as (age, >2 years) those satisfying following diagnosis criteria [16] : major criteria: (1) Loss of consciousness; (2) Rigidity; (3) Generalized convulsive movements; minor criteria: (1) Bitten tongue or injury sustained in falling; (2) Urinary incontinence; (3) Post-seizure fatigue; (4) Drowsiness; (5) Headache or muscle aches (positive diagnosis requires at least two major criteria and at least two minor criteria). The exclusion criteria were as follows: (1) provoked seizures only; (2) age under two years at the time of recruitment; (3) presence of a learning disability or an active psychiatric condition; (4) presence of a progressive neurological condition; (5) presence of cardiac, hepatic, or renal disorders, or severe hypertension; (6) status epilepticus alone; (7) current medication possibly affecting PB usage. Three healthy controls per case were chosen as a control group.
Follow-up procedures
Each participant was required to collect a one-month supply of PB in designated clinics; thus, monthly follow-up was conducted to monitor the treatment efficacy and adverse effect. Individuals who 'defaulted' on their monthly visits were not followed up and were taken as loss to follow-up. A follow-up questionnaire was given during each clinic visit by primary health care physicians. The patients' seizure-number of the previous month and the used AEDdose were recorded. This information was used to make dose adjustments and to assess adverse effects and adherence.
Outcome/end point identification
The epilepsy project was not started simultaneously in the involved counties; it was started successively; in one county after the other one, instead. The end points included death or withdrawal. In case of death, death registry was based on the death certificate prepared by the primary health care physician. Death registry was formulated by the designers of this study project. Death certificate was issued by a medical practitioner certifying the deceased state of a person and later entered in an official register of death.
According to our previous standard [12] , SUDEP is defined as the sudden unexpected death in an individual with epilepsy with or without evidence of seizure, and excluding documented known causes, where postmortem examination does not reveal anatomic or toxicologic causes. Those putative causes of death (COD) were classified according to the 10th revision of the International Classification of Diseases [17] . Death can be categorized as probable SUDEP when SUDEP is suspected but death is not directly clinically observed and when full postmortem and toxicological testing are not available [12, 18] . We diagnosed probable SUDEP cases encompassing those with no other observable or reported cause of death and besides those murdered or sentenced to death were not considered either. In consideration of the more limited application of autopsies in developing countries than Europe and North America, verbal autopsies are the most feasible way to investigate probable SUDEP in our setting [15] . As described in our previous report [12, 19] , the primary health care physicians conducted the verbal autopsies by facilitating an interview with the families and/or neighbors and/or close friends of the deceased person to determine the likely cause of death; the conducted interview sought clues and signs of death as cited by the interviewee and attempted to establish a history of any illness, including a longitudinal history of epilepsy. Supervising neurologists, with the advice of an expert in forensic medicine, discussed the final death diagnosis when the COD was unclear.
Risk factor selection
Risk factors were as follows: seizure frequency at baseline, which is the total number of seizures in a year prior to the recruitment; seizure frequency prior to SUDEP, which is the seizure number in a month prior to death in the probable SUDEP group; epilepsy duration; PB dose, which is the dosage the patient was receiving at the time of death and classified into low-dosage group (30-120 mg/day) and moderate/high-dosage group (150-240 mg/day). For PB compliance assessment, all of the patients were required to attend the monthly designated clinics to collect a one-month supply of PB. Patient adherence to PB was assessed by counting the remaining pills to evaluate any missed doses in the previous month. Good compliance was defined as less than or equal to two missing doses in the previous month; bad compliance indicated more than two missing doses.
Study design (control selection) and statistics
We used a retrospective (case-control) design for this study. Demographic and clinical information for all patients with convulsive epilepsy was recorded by primary health care physicians, submitted, and stored in an electronic database. Cases meeting the definition of probable SUDEP were included in this study as the probable SUDEP group. By the end of December 2013, 7231 cases with identified convulsive epilepsy were recruited into this project, and 236 deceased cases with death certificates became our potential data pool from which 35 cases of probable SUDEP were selected and investigated.
Three living controls with longer follow-up periods than the probable SUDEP case were randomly selected from the database and individually matched for age and sex. In detail, we first selected cases with an equal duration of the PB treatment as probable SUDEP and then randomly chose three cases that were individually matched for age and sex as controls. Demographic information and possible risk factors for SUDEP were retrieved for analysis. This study had two phases. The first phase was the period before the recruitment (before regular PB intervention), in which study cases did not receive regular AEDs (regular AED refers to anti-epileptic drug therapy in accordance with the standards of clinical guidelines); the seizure frequency at baseline originated from this phase. The second phase was the period after the recruitment, in which the study cases received PB intervention and follow up.
Variables including the seizure frequency at baseline, seizure frequency prior to probable SUDEP (a month prior to probable SUDEP), epilepsy duration, and PB dose prior to probable SUDEP were compared between the case and controls by using the x 2 test.
The seizure frequency prior to SUDEP was compared with the seizure frequency at a time point of the same length of follow-up in the controls. Identical time point criteria were applied to the parameter of PB dose. Given the limited sample size, variables with p < 0.1 were included (forward conditional method) in the conditional logistic regression analysis. SPSS 17.0 was used for statistical analysis, and significance was set at p < 0.05 (twosided).
Results
A total of 35 probable SUDEP (14.8%) out of 236 patient deaths with convulsive epilepsy were recruited in the present study, with a mean follow-up of 27.14 months (range of 1-71 months). Among the probable SUDEP cases, 4 cases (11.4%) were under 18 years, including 2 children (under 15 years; 5.7%). Details on patient characteristics are provided in Table 1 . Table 1 shows that the population distribution according to the onset age, seizure frequency at baseline, and seizure frequency prior to probable SUDEP significantly differed between the probable SUDEP cases and the controls. By contrast, the disease duration, history of no regular AEDs, PB dose prior to probable SUDEP, and PB compliance were not statistically different. The early-onset age and increased seizure frequency at baseline/prior to probable SUDEP indicated the increased risk of probable SUDEP.
Among the probable SUDEP, 13 cases (37.1%) were found in bed at night (possibly asleep), 20 cases (57.1%) were found on the ground, events of death were witnessed in 7 cases (20%), and 3 cases (8.6%) were reported to have been suffering suffocation.
The variables included in the conditional regression model and their odds ratios (OR) are listed in Table 2 . Three variables with significant differences remained in the model. The table shows that early-onset (10 years) seizures have a higher chance to develop into probable SUDEP than late-onset seizures. A high frequency of convulsive seizures in the past (frequency at baseline) and recent seizure occurrence within a month before death are both associated with a significantly increased risk of probable SUDEP.
Discussion
The cases of probable SUDEP in this study were from a large population with convulsive epilepsy in rural communities and may not be generalized for all people with epilepsy since only convulsive epilepsy was involved in recent study. A verbal autopsy was applied for all the cases because of the limited medical resources in less developed areas. The present cohort has the following characteristics: (1) all cases and controls with convulsive seizure type were recruited; (2) PB monotherapy was prescribed for all the participants under a uniform epilepsy management program; (3) continuous follow up was conducted to monitor the seizures and the individual treatment response to PB; (4) all participants shared similar socioeconomic profiles Note that nearly half of patients including those probable SUDEPs and those controls did not receive any medical treatment before entering into this study, which indicates a poor treatment situation in rural China as previous study reported [13] . To the best of our knowledge, this study is the first to focus on probable SUDEP in China, although some reports previously mentioned epilepsy mortality [12, 20, 21] . Given that SUDEP risk is increased by convulsive seizures [22] [23] [24] , the probable SUDEP might more likely occur in the present cohort. The number of males and females was similar in this current study, which is consistent with the results of a previous study [5, 25] ; however, other reports demonstrated opposite findings [6, 26, 27] . Considering our study design and limited sample size, we cannot address the issue of whether or not gender is an independent risk factor for probable SUDEP. Meanwhile, we cannot obtain clues on the influence of a history of AEDs on probable SUDEP. The rate of SUDEP increases with the duration of epilepsy in a cohort of patients with childhood-onset epilepsy [28] . In that study, there were 18 cases of sudden, unexplained death out of a cohort with 245 subjects during 40 years follow-up; however, our results failed to show duration as a risk factor. Drug compliance in this study was not a risk possibly because of the small sample. In the present study, PB monotherapy was applied, and dose increments were associated with poorly controlled seizures; thus, it is not ideal to investigate the drug changes in the present study. Among all the risk factors, lack of seizure freedom is the factor most strongly associated with an increased risk of probable SUDEP. In our study, seizure frequency at baseline (one year prior to regular PB treatment) and the latest seizure occurrence (recent one month seizures prior to death) are significant factors affecting probable SUDEP, in agreement with the results of several previous studies [5, 6, [22] [23] [24] . Another risk factor that was confirmed by our study is the early age of onset of epileptic seizures. The reason for this finding might be that epilepsy in childhood (equal to or less than 10 years) may have a higher risk for probable SUDEP, as previously suggested [25, 30] . In Nilsson study [24] , 57 SUDEP cases were included and OR of early-onset versus late-onset epilepsy was 7.72 in Shankar' review [29] , early age of onset of epilepsy (less than 15 years age) was present in 33 out of 48 SUDEP cases.
Limitations
There were also limitations in this study. Because the selfreport method was used to gather the information of seizure frequency at baseline, the data could be biased. Exclusion criterion used in this study could introduce some selecting bias (for example, in many contexts, cognitive impairment and epilepsy are commonly co-morbid, which might exclude some patients with such complications). Those patients lost to follow-up could not be traced, hence not all deaths got registered as some of them were lost to follow-up. Our study was not suitable for evaluating drug effects to SUDEP.
Conclusion
This study supports previous reports that an association exists between SUDEP and seizure frequency or early epilepsy-onset age. Special attention should be given to patients with early epilepsyonset and those with seizures despite antiepileptic treatment. In conclusion control of seizures is important to reduce the risk of probable SUDEP. Special education and surveillance are necessary for those with early-onset seizures. Further multi-center studies are needed on probable SUDEP in poor-resource areas.
